Objective and subjective measures of dalfampridine efficacy in clinical practice
Background Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patien...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
SAGE Publishing
2018-07-01
|
| Rangatū: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Urunga tuihono: | https://doi.org/10.1177/2055217318786742 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|